Sign in to enjoy up to 20% OFF or Register
  •  
[email protected]
Chemistry
Bioactive Molecules
Natural Products
ADCs
Antibodies
Multiplex IHC
Material Science
Others
+1 800-931-7508 [email protected]
Sign in to enjoy up to 20% OFF

[CAS NO. 191732-72-6]  Lenalidomide

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [191732-72-6]

Catalog
HY-A0003
Brand
MCE
CAS
191732-72-6

DESCRIPTION [191732-72-6]

Overview

MDLMFCD07772307
Molecular Weight259.26
Molecular FormulaC13H13N3O3
SMILESO=C1C2=CC=CC(N)=C2CN1C(C(N3)=O)CCC3=O

For research use only. We do not sell to patients.

26 Publications Citing Use of MCE


Summary

Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN) , and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells [1] [2] .


IC50 & Target

Cereblon


In Vitro

Lenalidomide is potent in stimulating T cell proliferation and IFN-γ and IL-2 production. Lenalidomide has been shown to inhibit production of pro inflammatory cytokines TNF-α, IL-1, IL-6, IL-12 and elevate the production of anti-inflammatory cytokine IL-10 from human PBMCs. Lenalidomide downregulates the production of IL-6 directly and also by inhibiting multiple myeloma (MM) cells and bone marrow stromal cells (BMSC) interaction, which augments the apoptosis of myeloma cells [2] . Dose-dependent interaction with the CRBN-DDB1 complex is observed with Thalidomide, Lenalidomide and Pomalidomide, with IC 50 values of ~30 μM, ~3 μM and ~3 μM, respectively, These reduced CRBN expression cells (U266-CRBN 60 and U266-CRBN 75 ) are less responsive than the parental cells to antiproliferative effects Lenalidomide across a dose-response range of 0.01 to 10 μM [3] . Lenalidomide, a thalidomide analog, functions as a molecular glue between the human E3 ubiquitin ligase cereblon and CKIα is shown to induce the ubiquitination and degradation of this kinase, thus presumably killing leukemic cells by p53 activation [5] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


In Vivo

The toxicity of Lenalidomide doses up to 15, 22.5, and 45 mg/kg via IV, IP, and PO routes of administration. Limited by solubility in our PBS dosing vehicle, these maximum achievable Lenalidomide doses are well tolerated with the exception of one mouse death (of four total dosed) at the 15 mg/kg IV dose. Notably, no other toxicities are observed in the study at IV doses of 15 mg/kg (n=3) or 10 mg/kg (n=45) or at any other dose level through IV, IP, and PO routes [4] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


Clinical Trial

NCT Number Sponsor Condition Start Date Phase
NCT03015792 Mayo Clinic|National Cancer Institute (NCI)
Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
March 10, 2017 Phase 1|Phase 2
NCT04635189 University of Rochester
Multiple Myeloma
July 27, 2021 Phase 2
NCT00525447 Seagen Inc.|Genentech, Inc.
Multiple Myeloma
August 2007 Phase 1

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 385.71 mM ; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.8571 mL 19.2857 mL 38.5713 mL
5 mM 0.7714 mL 3.8571 mL 7.7143 mL
10 mM 0.3857 mL 1.9286 mL 3.8571 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 2.5 mg/mL (9.64 mM); Clear solution

  • 2.

    Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (9.64 mM); Clear solution

  • 3.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: ≥ 2.5 mg/mL (9.64 mM); Clear solution

* All of the co-solvents are available by MCE.


Synonyms

2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-
3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidinedione
3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione
Revimid
CC 5013
CDC 501
Lenalidomide
Revlimid
1-Oxo-4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole
3-(4-Amino-1-oxoisoindolin-2-yl)piperidin-2,6-dione
ENMD 0997
IMiD 3
revlMiD

Information
Shipping
Privacy notice
Terms of Service
About us
Contact us
Customer services
Search
Custom Synthesis
My account
My account
Orders
Addresses
Shopping cart
Pay
Powered by Arctom Copyright © 2025 Arctom. All rights reserved.